Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biothera takes over Antisoma anticancer compound
In future, Biothera is planning to conduct trials with the combination therapy of Imprime PGG and AS1402. Imprime PGG is a new immunotherapy that works synergistically with anti-tumor
In future, Biothera is planning to conduct trials with the combination therapy of Imprime PGG and AS1402. Imprime PGG is a new immunotherapy that works synergistically with anti-tumor
Brenntag markets a diversified line of specialty and industrial chemicals for a variety of applications, including personal care, coatings, food & beverage, pharmaceuticals, textile, rubber, plastics & polymers,
In the study, 48 patients were evaluated with 0.1%w/w CT327 cream twice daily and nine patients treated with matching placebo. The study results suggested that CT327produced a good
The Knowledge Centre was opened to support Grace’s customers in the areas of laboratory separations, bulk purification, excipients and pharmaceutical intermediates. Grace’s expertise in the areas assists pharmaceutical
The funding will be used for the pre-clinical development of a novel vaccine to prevent meningitis B infection in children. Action Medical Research senior research evaluation manager Dr
The initial aim of the collaboration is to pursue a comprehensive and systematic approach to identify and develop physiological mechanisms and targets that regulate beta cell replication. Evotec
The open-labeled trial (GRASPALL-GRAALL SA2 2008) introduced GRASPA in a first-line treatment for Acute Lymphoblastic Leukemia (ALL) in patients older than 55 years. The clinical end point combines
Tris Pharma said if the drug will be approved by the FDA its extended release suspension will offer an alternative to the currently available immediate release formulations. The
TARIS is a specialty pharmaceutical company engaged in developing a pipeline of new therapeutics designed to leverage common, minimally invasive urologic procedures to deliver and maintain drug directly
The study is designed to determine the safety, efficacy, pharmacokinetics, pharmacodynamics of single doses of SAN-300. In the trial, the company is evaluating around 60 patients including healthy